SCHEMBL6915413

SCHEMBL6915413

CNC(=O)c1cnn(C)c1C(=O)Nc1ccn2cc(-c3ccc(F)cc3)nc2n1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 14/20 0.62
CSNK1D P48730 2/20 0.39
CSNK1E P49674 2/20 0.39
TP53 P04637 3/20 0.38
MAPT P10636 2/20 0.38
GAA P10253 1/20 0.37
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
USP2 O75604 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
CASP1 P29466 1/20 0.36
PPARG P37231 1/20 0.36
KMT2A Q03164 1/20 0.36
NCOA2 Q15596 1/20 0.36
NCOA1 Q15788 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HSD17B10 Q99714 1/20 0.36
NR2E3 Q9Y5X4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14672685 0.91 PDE10A (0.65) PDE10ACSNK1DCSNK1ETP53MAPT
SCHEMBL12316438 0.90 PDE10A (0.74) PDE10A
SCHEMBL6917345 0.89 PDE10A (0.61) PDE10ATP53GAA
SCHEMBL2374049 0.87 PDE10A (0.62) PDE10ACSNK1DCSNK1EGAAKDM4E
SCHEMBL6916379 0.84 PDE10A (0.61) PDE10ATP53MAPTKDM4EALDH1A1
SCHEMBL12314872 0.84 PDE10A (0.61) PDE10AMAPTKDM4EMEN1ALDH1A1
SCHEMBL2397443 0.82 PDE10A (0.77) PDE10A
SCHEMBL2384937 0.82 PDE10A (0.73) PDE10ATP53MAPTKDM4EALDH1A1
SCHEMBL2384493 0.81 PDE10A (0.71) PDE10AMAPTGAAALDH1A1HPGD
SCHEMBL14672680 0.81 PDE10A (0.64) PDE10ATP53GAAKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2552918-B1 N-(IMIDAZOPYRIMIDIN-7-YL)-HETEROARYLAMIDE DERIVATIVES AND THEIR USE AS PDE10A INHIBITORS HOFFMANN LA ROCHE (CH) 2014-06-11 EP disclosed
US-8410117-B2 Imidazopyrimidine derivatives HOFFMANN-LA ROCHE INC. (US) 2013-04-02 US disclosed
US-20110237564-A1 IMIDAZOPYRIMIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. 2011-09-29 US disclosed
WO-2011117264-A1 N-(IMIDAZOPYRIMIDIN-7-YL)-HETEROARYLAMIDE DERIVATIVES AND THEIR USE AS PDE10A INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2011-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237564-A1 IMIDAZOPYRIMIDINE DERIVATIVES PDE5A, PDE3B, PDE3A PDE10A 10/4885CSNK1D 463/4885CSNK1E 551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.